VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VTRS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
VTRSViatris Inc.
$16.23$18.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksVTRSFinancials

Viatris Inc. (VTRS) Financials

22Y historyFree accessUpdated daily

Revenue growth remains highly unstable, with gross margins compressing significantly from 41.6% in 2023Q4 to 32.9% in 2026Q1 due to intensifying competitive pressures.

VTRS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Mar'06Mar'05Mar'04
Sales/Revenue14.56B14.3B14.74B15.43B16.26B17.89B11.95B11.5B11.43B11.91B11.08B9.43B7.72B6.91B6.8B6.13B5.45B5.09B5.14B2.91B1.26B1.25B1.37B
Revenue Growth %1.62%-2.98%-4.46%-5.14%-9.08%49.73%3.87%0.58%-3.98%7.5%17.47%22.15%11.73%1.66%10.87%12.46%7.02%-0.87%76.85%131.08%0.3%-8.82%-
Cost of Goods Sold9.55B9.29B9.12B8.99B9.77B12.31B8.15B7.6B7.43B7.12B6.38B5.21B4.19B3.87B3.89B3.57B3.23B3.02B3.07B1.74B629.55M629.83M612.15M
COGS % of Revenue-64.94%61.85%58.26%60.05%68.83%68.22%66.11%65%59.83%57.6%55.29%54.3%56%57.21%58.18%59.32%59.27%59.7%59.86%50.08%50.25%44.53%
Gross Profit5.01B5.01B5.62B6.44B6.5B5.58B3.8B3.9B4B4.78B4.7B4.22B3.53B3.04B2.91B2.56B2.22B2.07B2.07B1.17B627.62M623.54M762.47M
Gross Margin %34.4%35.06%38.15%41.74%39.95%31.17%31.78%33.89%35%40.17%42.4%44.71%45.7%44%42.79%41.82%40.68%40.73%40.3%40.14%49.92%49.75%55.47%
Gross Profit Growth %--10.85%-12.66%-0.9%16.53%46.85%-2.59%-2.6%-16.34%1.83%11.41%19.5%16.04%4.54%13.46%15.6%6.89%0.21%77.56%85.77%0.65%-18.22%-
Operating Expenses4.87B7.68B5.61B5.67B4.88B5.61B4.01B3.18B3.1B3.35B4B2.76B2.18B1.9B1.8B1.56B1.5B1.55B1.77B794.21M340.23M321.37M267.67M
OpEx % of Revenue-53.68%38.09%36.77%30.02%31.36%33.55%27.67%27.08%28.1%36.09%29.22%28.18%27.57%26.47%25.42%27.44%30.46%34.5%27.34%27.06%25.64%19.47%
Selling, General & Admin3.77B3.79B4.43B4.65B4.18B4.53B3.34B2.56B2.44B2.58B2.5B2.18B1.63B1.41B1.39B1.21B1.09B1.05B1.05B599.46M225.38M259.11M201.61M
SG&A % of Revenue-26.53%30.03%30.14%25.7%25.32%28%22.29%21.35%21.63%22.56%23.13%21.06%20.39%20.49%19.82%19.94%20.62%20.51%20.64%17.93%20.67%14.67%
Research & Development992.5M965.9M808.7M805.2M662.2M681M512.6M639.9M704.5M783.3M826.8M671.9M581.8M507.8M401.3M294.73M282.15M275.26M317.22M194.75M102.43M88.25M100.81M
R&D % of Revenue-6.75%5.49%5.22%4.07%3.81%4.29%5.56%6.16%6.58%7.46%7.13%7.54%7.35%5.9%4.81%5.18%5.4%6.17%6.7%8.15%7.04%7.33%
Other Operating Expenses1000K2.92B379.2M217.1M40.8M399.3M150.3M-21.4M-49.5M-13.1M672.5M-97.4M-32.1M-11.5M5.2M48.56M127.06M225.72M401.63M012.42M-25.99M-34.76M
Operating Income139.4M-2.66B10.1M766.2M1.61B-34M-210.8M715.5M905.6M1.44B699.2M1.46B1.35B1.14B1.11B1.01B721.58M523.35M297.88M371.72M287.39M302.17M494.8M
Operating Margin %0.96%-18.62%0.07%4.97%9.93%-0.19%-1.76%6.22%7.92%12.07%6.31%15.49%17.52%16.43%16.32%16.4%13.24%10.28%5.8%12.8%22.86%24.11%36%
Operating Income Growth %--26467.33%-98.68%-52.55%4849.71%83.87%-129.46%-20.99%-36.99%105.55%-52.14%8.01%19.12%2.35%10.34%39.34%37.88%75.69%-19.86%29.34%-4.89%-38.93%-
EBITDA2.32B135.2M2.9B3.51B4.64B4.47B2.01B2.73B3.02B3.24B2.22B2.49B1.92B1.65B1.66B1.52B1.14B924.51M723.16M582.11M334.21M347.27M539.12M
EBITDA Margin %15.93%0.95%19.7%22.73%28.55%25.01%16.79%23.78%26.37%27.23%20.06%26.44%24.86%23.9%24.37%24.73%21%18.15%14.08%20.04%26.58%27.71%39.22%
EBITDA Growth %1209.76%-95.34%-17.21%-24.47%3.8%123.03%-26.67%-9.31%-7.02%45.94%-10.86%29.9%16.21%-0.27%9.22%32.49%23.78%27.84%24.23%74.17%-3.76%-35.59%-
D&A (Non-Cash Add-back)2.13B2.8B2.89B2.74B3.03B4.51B2.22B2.02B2.11B1.81B1.52B1.03B566.6M516M546.6M510.69M422.79M401.16M425.28M210.4M46.83M45.1M44.32M
EBIT-244.4M-3.19B-73.2M776M3.41B-28.2M-223.4M671.7M840.7M1.44B576.5M1.25B1.31B1.06B1.11B990.58M687.41M545.47M309.22M-1.2B287.39M302.17M494.8M
Net Interest Income-475.9M-471.3M-550M-573.1M-592.4M-636.2M-497.8M-517.3M-542.3M-534.6M-442.5M-336.4M-333.2M-313.3M-308.7M-335.94M-331.46M-318.5M-357.05M0-31.29M00
Interest Income000000000012.3M0000006.7M00000
Interest Expense475.9M471.3M550M573.1M592.4M636.2M497.8M517.3M542.3M534.6M454.8M336.4M333.2M313.3M319M333.1M277.96M266.75M380.78M239.21M31.29M00
Other Income/Expense-954.7M-1B-633.3M-563.3M1.2B-630.4M-510.4M-561.1M-607.2M-534.2M-577.5M-545.5M-378.1M-388.2M-305.2M-350.81M-365.64M-296.38M-345.71M-1.81B-12.78M10.08M17.81M
Pretax Income-815.3M-3.67B-623.2M202.9M2.81B-664.4M-721.2M154.4M298.4M903M121.7M915.4M974.5M747.3M804.08M654.64M355.94M226.97M-71.56M-1.44B274.61M312.25M512.61M
Pretax Margin %-5.6%-25.63%-4.23%1.32%17.3%-3.71%-6.04%1.34%2.61%7.58%1.1%9.71%12.62%10.82%11.83%10.68%6.53%4.46%-1.39%-49.62%21.84%24.91%37.29%
Income Tax-518.8M-150.1M11M148.2M734.6M604.7M-51.3M137.6M-54.1M207M-358.3M67.7M41.4M120.8M161.15M115.83M10.4M-20.77M128.55M80.1M90.06M108.66M178M
Effective Tax Rate %63.63%4.1%-1.77%73.04%26.11%-91.01%7.11%89.12%-18.13%22.92%-294.41%7.4%4.25%16.16%20.04%17.69%2.92%-9.15%-179.65%-5.56%32.8%34.8%34.72%
Net Income-296.5M-3.51B-634.2M54.7M2.08B-1.27B-669.9M16.8M352.5M696M480M847.6M929.4M623.7M640.85M536.81M345.12M232.57M-196.08M-1.52B184.54M203.59M334.61M
Net Margin %-2.04%-24.58%-4.3%0.35%12.78%-7.1%-5.61%0.15%3.08%5.85%4.33%8.99%12.04%9.03%9.43%8.76%6.33%4.57%-3.82%-52.23%14.68%16.24%24.34%
Net Income Growth %92.18%-454.23%-1259.42%-97.37%263.79%-89.45%-4087.5%-95.23%-49.35%45%-43.37%-8.8%49.01%-2.68%19.38%55.55%48.39%218.61%87.08%-922.23%-9.36%-39.16%-
Net Income (Continuing)-296.5M-3.51B-634.2M54.7M2.08B-1.27B-669.9M16.8M352.5M696M480M847.7M933.1M626.5M642.93M538.8M345.54M247.75M-200.11M-1.52B184.54M203.59M334.61M
Discontinued Operations00000000000000000000000
Minority Interest00000000001.4M1.4M20.1M18.1M15.11M13.01M13.52M14.05M29.11M34.33M000
EPS (Diluted)-0.25-3.00-0.530.051.71-1.05-1.110.030.681.300.921.702.341.581.521.220.680.30-0.64-5.900.790.741.21
EPS Growth %91.68%-466.04%-1269.98%-97.35%262.86%5.41%-3800%-95.59%-47.69%41.3%-45.88%-27.35%48.1%3.95%24.59%79.41%126.67%146.88%89.15%-846.84%6.76%-38.84%-
EPS (Basic)--3.00-0.530.051.71-1.05-1.110.030.691.300.941.802.491.631.541.250.690.31-0.64-5.900.800.761.24
Diluted Shares Outstanding1.18B1.17B1.19B1.21B1.22B1.21B601.2M516.5M516.5M536.7M520.5M497.4M398M394.5M420.24M438.79M328.98M306.91M304.36M257.15M234.21M273.62M276.32M
Basic Shares Outstanding1.16B1.17B1.19B1.2B1.21B1.21B601.2M560M516.5M535.38M520.5M497.4M397.18M394.5M415.21M430.84M324.45M305.16M304.36M257.15M229.39M268.99M268.93M
Dividend Payout Ratio---1052.29%27.98%-----------40.29%---26.97%15.85%7.78%

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Regulatory Pricing Erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Volatility Masks Underlying Erosion

According to the provided quarterly income statements, Viatris experienced a revenue growth fluctuation ranging from a 11.2% contraction in 2025Q1 to an 8.1% expansion in 2026Q1, highlighting the inherent instability of a portfolio heavily reliant on legacy assets and complex divestiture-driven revenue adjustments.

The recent return to positive growth in 2026Q1 appears to be an outlier rather than a structural shift, given the preceding multi-quarter trend of contraction. Investors should monitor whether this growth is sustainable or merely a temporary result of product mix shifts following the divestiture of the biosimilars business.

Structural Margin Compression Remains Evident

As reported in financial statements, Viatris's gross margin has trended downward from a peak of 41.6% in 2023Q4 to 32.9% in 2026Q1, suggesting that the company is struggling to maintain pricing power amidst intensifying competition and the loss of high-margin legacy brand exclusivity.

The consistent erosion of gross margins indicates that the company's 'Global Healthcare Gateway' may be losing its ability to command premiums for off-patent molecules. This compression warrants further investigation into whether the current cost structure is optimized for a lower-margin, high-volume generic reality.

GAAP Earnings Obscured by Volatility

Based on Viatris's reported figures, net income has exhibited extreme volatility, swinging from a $3.0 billion loss in 2025Q1 to a $176.4 million profit in 2026Q1, largely driven by non-operating charges and restructuring costs that frequently decouple reported earnings from actual operational performance.

The frequent appearance of negative net margins suggests that the company is still absorbing the financial consequences of its merger and subsequent portfolio right-sizing. Analysts should treat GAAP net income with skepticism, as it appears heavily influenced by non-cash impairments rather than core pharmaceutical demand.

Sustainability of Legacy Cash Flows

Data from recent filings suggests that the market's skepticism regarding Viatris's terminal value may be justified, as the company's operating income has frequently dipped into negative territory, raising concerns about the long-term viability of its business model in the face of global regulatory pricing pressures.

Short-sellers likely focus on the persistent gap between the company's stated strategy and its inability to generate consistent operating profit. The reliance on divestitures to manage debt levels may indicate that the underlying business is not generating sufficient organic cash flow to support its current capital structure.

VTRS — Frequently Asked Questions

Quick answers to the most common questions about buying VTRS stock.

What was Viatris Inc.'s (VTRS) revenue in 2025?

For fiscal year 2025, Viatris Inc. (VTRS) reported total revenue of $14.30B. This represents a 940.3% increase compared to $1.37B in 2003.

Is Viatris Inc. (VTRS) profitable?

Viatris Inc. (VTRS) reported a net loss of $3.51B for the fiscal year ending 2025.

What is Viatris Inc.'s operating profit margin?

Viatris Inc. (VTRS) reported an operating income of $-2663.1M, resulting in an operating profit margin of -18.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Viatris Inc.'s gross profit and gross margin?

Viatris Inc. (VTRS) generated $5.01B in gross profit for the year, representing a gross profit margin of 35.1%. This demonstrates the company's core pricing power and production efficiency.